Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl
about
Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activityMetabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteinsAPOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal CanadiansAnion-exchange HPLC separation of five major rabbit lipoproteins using a nonporous diethylaminoethyl-ligated gel with a perchlorate-containing eluent.Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulationConstitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease.Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects.Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic miceApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African AmericansApolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma.Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein EHyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1.ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.Apolipoprotein C-I binds more strongly to phospholipid/triolein/water than triolein/water interfaces: a possible model for inhibiting cholesterol ester transfer protein activity and triacylglycerol-rich lipoprotein uptake.Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes.The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosisReversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice.Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase.Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice.Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in PSwt-1 cells.Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL.Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome.Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein.
P2860
Q24290207-526FA85C-6C4F-40CC-8EB4-3A36BB9A3A72Q24651503-CA7AFED3-50E3-4A85-9D70-3AFBF7861AADQ33741245-7BF97639-B230-4D16-95D5-BB1C6F283521Q33993189-B1D37B89-066F-4D8A-A5AC-6D2FE1927299Q34089899-F5DB1028-51F3-44D9-B937-F36EF1FC1FCEQ35958497-09639F56-7352-4403-9C2C-24899C2E1CCAQ36745091-8AA66966-2124-4BE0-80A0-48B54EB165A5Q36930204-D418274B-EC80-467A-A045-2252F1A544AFQ37202057-4AB2CA83-2458-45EC-8476-8AF1F511947DQ37222426-84E68765-6167-4D8D-ACCD-67F58F89943EQ37299858-1024E0C0-84CB-4352-9046-C5A4D447FA9CQ37333795-5EED0172-DBE0-48A5-907D-4C8D9BC7461EQ37368158-1A878A38-9456-46A5-92FB-097E7C1E5756Q37376984-A6FD9429-EA3A-4C24-9C67-EF2569805918Q39614082-6D8BEE58-F286-46EA-B882-E58772779AB3Q41825540-CA58C50D-2B61-4946-9815-AC41D112CF8BQ42114918-4ADDD7CE-CB5B-41DD-B438-D09629199A00Q42400268-3E9423C8-A242-4124-ACEC-9F6D9D06FF00Q42825544-6FE5869B-BB75-4AA4-B44F-09B1FB2BC5E5Q42992915-B5ABAF40-4853-4185-9262-59842515D7F3Q44031811-FF1A6883-4342-43C6-A784-C5169569A2D1Q44168307-671F0AC1-2CD1-4EBF-8A41-66918DE05BC2Q44231224-CE755049-2E86-4181-8508-699DE0A4E0CDQ45041090-82642838-7962-400D-A9C4-12D5FF7ED4DEQ45064225-C90B3BDB-909B-41FF-BAF5-DFE7FBBC0B02Q46990753-E6C0DA43-C77E-401A-ADF9-47367A931807Q52595654-D42A516B-A99E-4508-953F-B0C3C5C350DDQ54575442-B9A6008E-4D32-420E-98F3-4C32A35A2126
P2860
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl
@en
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.
@nl
type
label
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl
@en
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.
@nl
prefLabel
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl
@en
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.
@nl
P2093
P2860
P356
P1476
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl
@en
P2093
H N Ginsberg
J L Breslow
N S Shachter
R Ramakrishnan
P2860
P304
P356
10.1172/JCI118857
P407
P577
1996-08-01T00:00:00Z